Home
NICE Guidance
Conditions and diseases
Cancer
Breast cancer
Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer
Clinical guideline [CG164]
Published date:
June 2013
Last updated:
March 2017
Guidance
Tools and resources
Information for the public
Evidence
History
Filter
Type
Cost Saving Guidance
Do not do
Key Therapeutic Topic
Public Health ROI tool
QP Case Study
Cochrane Topic
Published
2017
2016
2015
2014
2013
2012
Impact Level
Very Low
Low
High
Very High
Unclassified
Exclude
Varies locally
Do not routinely offer ultrasound surveillance to women at moderate or high risk of breast cancer but consider it: -when MRI surveillance would normally be offered but is not suitable (for example, because of claustrophobia) - when results of mammography or MRI are difficult to interpret.
Do not do
June 2013
Unclassified
Do not offer mammographic surveillance to women: - aged 29 years and under - aged 30 to 39 years at moderate risk of breast cancer - aged 30 to 49 years who have not had genetic testing but have a greater than 30% probability of being a TP53 carrier - of any age with a known TP53 mutation.
Do not do
June 2013
Unclassified
Do not offer MRI surveillance to any women aged 50 years and over without a TP53 mutation unless mammography has shown a dense breast pattern.
Do not do
June 2013
Unclassified
Do not offer surveillance to women who have undergone a bilateral mastectomy.
Do not do
June 2013
Unclassified
Women should not be prescribed the oral contraceptive pill purely for prevention of cancer, although in some situations reduction in ovarian cancer risk may outweigh any increase in risk of breast cancer.
Do not do
June 2013
Unclassified
Do not offer tamoxifen or raloxifene to women who were at high risk of breast cancer but have had a bilateral mastectomy.
Do not do
June 2013
Unclassified
Do not offer risk-reducing surgery (for people with personal history of breast cancer) to people with comorbidities that would considerably increase the risks of surgery.
Do not do
June 2013
Unclassified
Do not offer risk-reducing surgery (for people with personal history of breast cancer) to people who have a limited life expectancy from their cancer or other conditions.
Do not do
June 2013
Unclassified
Do not continue treatment with tamoxifen or raloxifene beyond 5 years for chemoprevention in women with no personal history of breast cancer
Do not do
June 2013
Unclassified
Do not offer MRI to women:-of any age at moderate risk of breast cancer- of any age at high risk of breast cancer but with a 30% or lower probability of being a BRCA or TP53 carrier- aged 20 to 29 years who have not had genetic testing but have a greater than 30% probability of being a BRCA carrier- aged 20 to 29 years with a known BRCA1 or BRCA2 mutation- aged 50 to 69 years who have not had genetic testing but have a greater than 30% probability of being a BRCA or a TP53 carrier, unless mammography has shown a dense breast pattern- aged 50 to 69 years with a known BRCA1 or BRCA2 mutation, unless mammography has shown a dense breast pattern.See also: CG164 Summary of recommendations on surveillance for women with no personal history of breast cancer.
Do not do
June 2013
Unclassified
Show
10
25
50
All